Tumorimmunologische Strategien in der Dermatoonkologie

Zusammenfassung

Während hämatologische Neoplasien zunehmend besser therapeutisch angehbar sind, ist die Behandlung solider Tumoren einschließlich des malignen Melanoms insbesondere im metastasierten Stadium nach wie vor limitiert. Der Zuwachs an tumorimmunologischem Wissen in den letzten 10 Jahren hat zur Identifikation von einer Vielzahl von Melanom-assoziierten Tumorantigenen geführt als auch zur Entwicklung von unterschiedlichen Behandlungskonzepten. Im Folgenden sollen die Fortschritte der letzten Jahre knapp zusammengefasst werden, wobei das Hauptaugenmerk auf Peptide und dendritische Zellen gelegt wurde.

Abstract

Haematologic neoplasms can be treated more and more successfully in contrast to solid tumors including malignant melanoma. Especially in the advanced stage of disease no effective treatment options are available. Over the last decade a substantial surplus of tumor immunological knowledge could be witnessed leading to the identification of numerous tumor-associated antigens and consequently to the design of various novel treatment regimens. In this chapter the progress which was made particularly in the field of peptide and dendritic cell vaccinationis is briefly summarized.

Literatur

• 1 Schadendorf D. Is there a standard for the palliative treatment of melanoma?.  Onkologie. 2002;  25 74-76
• 2 Bell D. et al . Dendritic cells.  Adv Immunol. 1999;  72 255-324
• 3 Rosenberg S A. Progress in human tumor immunology and immunotherapy.  Nature. 2001;  411 380-384
• 4 Wang R F. Human tumor antigens: implications for cancer vaccine development.  J Mol Med. 1999;  77 640-655
• 5 Marchand M. et al . Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1.  Int J Cancer. 1999;  80 219-230
• 6 Rosenberg S A. et al . Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma.  Nat Med. 1998;  4 321-327
• 7 Jaeger E. et al . GM-CSF enhances immune responses to melanoma-associated peptides in vivo.  Int J Cancer. 1996;  67 54-62
• 8 Scheibenbogen C. et al . Phase II trial of vaccination with tyrosinase peptides and GM-CSF in melanoma.  J Immunotherapy. 2000;  23 275-281
• 9 Scheibenbogen C. et al . Long-term freedom from recurrence in 2 stage IV melanoma patients following vaccination with tyrosinase peptides.  Int J Cancer. 2002;  99 403-408
• 10 Wang F. et al . Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma.  Clin Cancer Res. 1999;  5 2756-2765
• 11 Lee P. et al . Effects of IL-12 on the immune response to a multipeptide vaccine for resected melanoma.  J Clin Oncol. 2001;  19 3836-3847
• 12 Slingluff C. et al . Phase I trial of a melanoma vaccine with gp100 280 -288 peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcome.  Clin Cancer Res. 2001;  7 3012-3024
• 13 Scheibenbogen C. et al . Effects of granulocyte-macrophage colony-stimulating factor and foreign helper protein as immunologic adjuvants on the T-cell response to vaccination with tyrosinase peptides.  Int J Cancer. 2003;  104 188-194
• 14 Banchereau J, Steinman R M. Dendritic cells and the control of immunity.  Nature. 1998;  392 245-252
• 15 Romani N. et al . Proliferating dendritic cell progenitors in human blood.  J Exp Med. 1994;  180 83-93
• 16 Jonuleit H. et al . Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions.  Eur J Immunol. 1997;  27 3135-3142
• 17 Nestle F O. et al . Dendritic cells: On the move from bench to bedside.  Nat Med. 2001;  7 761-765
• 18 Fernandez N C. et al . Dendritic cells directly trigger NK cell function: cross talk relevant in innate anti-tumor immune responses in vivo.  Nature Med. 1999;  5 405-411
• 19 Chikamatsu K. et al . Generation of anti-p53 cytotoxic T lymphocytes from human peripheral blood using autologous dendritic cells.  Clin Cancer Res. 1999;  5 1281-1288
• 20 Sun Y. et al . Identification of a new HLA-A(*)0201-restricted T-cell epitope from the tyrosinase-related protein 2 (TRP2) melanoma antigen.  Int J Cancer. 2000;  87 399-404
• 21 Sun Y. et al . Expression of the proteasome activator PA28 rescues the presentation of a cytotoxic T lymphocyte epitope on melanoma cells.  Cancer Res. 2002;  62 2875-2882
• 22 Storkus W P. et al . Identification of T-cell epitopes: rapid isolation of class I-presented peptides from viable cells by mild acid elution.  J Immunother. 1993;  14 94-103
• 23 Nair S K. et al . Induction of carcinoembryonic antigen (CEA)-specific cytotoxic T-lymphocyte responses in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA.  Int J Cancer. 1999;  82 121-124
• 24 Thomas R. et al . Immature human monocyte-derived dendritic cells migrate rapidly to draining lymph nodes after intradermal injection for melanoma immunotherapy.  Melanoma Res. 1999;  9 474-481
• 25 Morse M A. et al . Migration of human dendritic cells after injection in patients with metastatic malignancies.  Cancer Res. 1999;  59 56-58
• 26 Nestle F O. et al . Vaccination of melanoma patients with peptide or tumor lysate pulsed dendritic cells.  Nat Med. 1998;  4 328-332
• 27 Thurner B. et al . Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma.  J Exp Med. 1999;  190 1669-1678
• 28 Schuler-Thurner B. et al . Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1+ melanoma patients by mature monocyte-derived dendritic cells.  J Immunol. 2000;  165 3492-3496
• 29 Dudley M E. et al . Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes.  Science. 2002;  298 850-854
• 30 Sun Y. et al . Cell-based vaccination against melanoma - background, preliminary results, and perspective.   J Mol Med. 1999;  77 593-608